Regeneron, Alexion Big-Cap Biotechs Sales Seen RisingBig-cap biotechs Regeneron (REGN) and Alexion (ALXN) are both set to report Q4 results before the open Thursday, and both are expected to report double- or even triple-digit sales and earnings growth. Analysts expect Regeneron to have the steeper sales growth, as it's still ramping up its vision-loss drug Eylea after its approval in November 2011. Analysts polled by Thomson Reuters expect revenue of $392.64 million, up 219% from the year-earlier
Source:
Regeneron, Alexion Big-Cap Biotechs Sales Seen RisingLinkback:
https://tubagbohol.mikeligalig.com/index.php?topic=68722.0
Topic: Technology: Regeneron, Alexion Big-Cap Biotechs Sales Seen Rising (Read 425 times)